PT  - JOURNAL ARTICLE
AU  - Li Ma
AU  - Adriana Prada
AU  - Michael Schmidt
AU  - Eric M. Morrow
TI  - Generation of Pathogenic <em>TPP1</em> Mutations in Human Stem Cells as a Model for CLN2 Disease
AID  - 10.1101/2021.01.05.425495
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.01.05.425495
4099  - http://biorxiv.org/content/early/2021/01/06/2021.01.05.425495.short
4100  - http://biorxiv.org/content/early/2021/01/06/2021.01.05.425495.full
AB  - Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is an autosomal recessive neurodegenerative disorder generally with onset at 2 to 4 years of age and characterized by seizures, loss of vision, progressive motor and mental decline, and premature death. CLN2 disease is caused by loss-of-function mutations in the tripeptidyl peptidase 1 (TPP1) gene leading to deficiency in TPP1 enzyme activity. Approximately 60% of patients have one of two pathogenic variants (c.509-1G>C or c.622C>T [p.(Arg208*)]). In order to generate a human stem cell model of CLN2 disease, we used CRISPR/Cas9-mediated knock-in technology to introduce these mutations in a homozygous state into H9 human embryonic stem cells. Heterozygous lines of the c.622C>T (p.(Arg208*)) mutation were also generated, which included a heterozygous mutant with a wild-type allele and different compound heterozygous coding mutants resulting from indels on one allele. We describe the methodology that led to the generation of the lines and provide data on the initial validation and characterization of these CLN2 disease models. Notably, both mutant lines (c.509-1G>C and c.622C>T [p.(Arg208*)]) in the homozygous state were shown to have reduced or absent protein, respectively, and deficiency of TPP1 enzyme activity. These models, which we are making available for wide-spread sharing, will be useful for future studies of molecular and cellular mechanisms underlying CLN2 disease and for therapeutic development.Competing Interest StatementThe authors have declared no competing interest.